New research explores Argyrin B and probiotics for gut health

Researchers have identified new therapeutic potential for microorganisms and natural substances in treating gut infections and environmental toxin exposure.

A research team involving the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and other German institutions has demonstrated that the natural substance Argyrin B effectively targets Clostridioides difficile (C. difficile). Unlike broad-spectrum antibiotics, which often damage beneficial gut bacteria, Argyrin B appears to kill the pathogen while largely sparing the healthy gut microbiome. This finding, published in npj Antimicrobials and Resistance, offers a potential new approach to treating antibiotic-associated diarrhea and life-threatening intestinal inflammation.

In separate research, studies are exploring the use of probiotics and paraprobiotics for wound healing and toxin removal. Researchers at the Pasteur Institute of Iran found that non-viable probiotics could help reduce inflammation and promote tissue repair in mouse models of infected burns. Additionally, the WIK's Kimchi Functionality Research Group discovered that the strain Leuconostoc mesenteroides CBA3656, isolated from fermented vegetables, has the ability to absorb nanoplastics within the gastrointestinal tract.